A research team at the University of Hong Kong's LKS Faculty of Medicine has unveiled a breakthrough biotechnology tool called RNA Segment Editing, or RSE. The approach functions as a "cut-and-patch" mechanism for RNA, allowing scientists to precisely remove or replace faulty sections of genetic messages within living cells. Crucially, the technique achieves this without permanently altering the underlying DNA.
This advance could significantly impact treatment strategies for neurodegenerative diseases, where faulty genetic instructions often play a central role. By editing RNA — the messenger that translates DNA into proteins — the tool offers a reversible and potentially safer alternative to permanent gene editing.
The RSE method operates at the post-transcriptional level, meaning it corrects errors after DNA has been transcribed into RNA. This allows precise excision of defective segments and insertion of correct sequences, effectively repairing the blueprint for protein production. The team demonstrated the technique's feasibility in cellular models, though specific success rates or target diseases were not detailed in the announcement.
Further validation in animal models and human cells will be necessary before clinical applications become feasible. Regulatory hurdles and delivery mechanisms for therapeutic use also remain unresolved. The HKUMed team is now exploring partnerships to advance the technology toward clinical trials.
One potential limitation is the risk of off-target edits or unintended RNA alterations, which could cause unpredictable side effects. The team acknowledges that extensive safety testing is required before RSE can be considered for human therapies.